New collaborative research shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study, which was led by a team from Roswell Park Comprehensive Cancer Center and involved contributors from six centers, is detailed in a presentation at the American Society of Clinical Oncology 2021 virtual annual meeting (abstract 4568).
In a new article published in Cancer Immunology Research, the Moffitt team shows that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models and may be a potential treatment option for patients with advanced melanoma.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
UC San Diego researchers discovered that tumor cells in younger and female patients accumulate cancer-causing mutations that are more poorly presented to the immune system, better enabling tumors to escape detection and clearance.
UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
UC San Diego researchers uncovered in mice how IRE1α, a molecule involved in cells’ response to stress, determines whether macrophages promote inflammation in the tumor microenvironment. Inflammation is known to promote tumor growth, making IRE1α an attractive target for drug development.
An interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center has developed a medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors to help boost the immune response and kill cancer cells.
Latest analysis of the global PD-1/PD-L1 immunotherapy clinical development pipeline reveals dramatic growth over past two years in number of trials, drug combinations, and drug targets, but lower patient recruitment rates in the U.S. compared to China.
A new study published this week gives insight into how cancer immunotherapies might one day be delivered directly to the brain in order to treat brain tumors.